---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-078611"
form_type: "8-K"
ticker: "BNBX"
cik: "0000744452"
company_name: "BNB PLUS CORP."
filed_at: "2025-08-14T23:59:59+00:00"
generated_at: "2026-05-17T13:45:44.989643+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Applied DNA Q3 FY2025 revenue $304K, operating loss $3.7M; cash burn improves 19% sequentially

## Summary
- Total revenues $304K (down 36% YoY from $473K); operating loss $3.7M vs $3.3M loss in prior year.
- Adjusted EBITDA negative $3.9M; monthly net cash burn $934K, down 19% sequentially and 25% YoY.
- Received follow-on LineaDNA order >$600K from IVD manufacturer; added new U.S. mRNA CDMO customer.
- Cash and equivalents $4.7M at June 30, 2025, including $723K from warrant exercises.
- Company closed MDx Testing Services (discontinued ops) and executed 1:15 reverse stock split in June.

## SEC filing metadata
- accession: 0001104659-25-078611
- form_type: 8-K
- ticker: BNBX
- cik: 0000744452
- company_name: BNB PLUS CORP.
- filed_at: 2025-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/744452/000110465925078611/0001104659-25-078611-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/744452/000110465925078611/tm2523531d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-078611
- JSON: https://secwatch.observer/filing/0001104659-25-078611.json
- Plain text: https://secwatch.observer/filing/0001104659-25-078611.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.